nference
PrivateLast Round
Accelerator
Dec 1, 2022
Total Funding Raised
$134.1M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
nference operates in Healthcare & Life Sciences and is based in Cambridge, Massachusetts. Its latest recorded funding round was an Accelerator round in December 2022.
nference is a health technology company that develops an AI-driven software platform to convert unstructured data from electronic medical records into actionable insights for pharmaceutical, biotechnology, and healthcare organizations.
Sector
Healthcare & Life Sciences
Verticals
Healthcare Analytics, Drug Discovery, Clinical Trials, EHR & EMR, NLP & Conversational AI
Business Model
B2B
Customer Profile
Services & Consulting, Subscription SaaS, Data as a Service
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
nference Comparables
Compare nference with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| TriNetX | 88% | |
| Truveta | 87% | |
| Verana Health | 86% |
For institutional investors. Book with your work email.
nference Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Accelerator | Dec 1, 2022 | ||||
| Series C | Dec 15, 2020 | ||||
| Series B | Jan 8, 2020 | ||||
| Series A | Jun 6, 2018 | ||||
| Seed | Jan 10, 2016 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
nference Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Matrix | Seed, Series B, Series A, Series C |
| PharmStars | Accelerator |
| Mayo Clinic Ventures | Series C |
| Matrix Capital Management | Series A, Series B, Series C |
| NTTVC | Series C, Series B |
| Mayo Clinic Ventures | Series C, Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 25, 2026
Monthly visitors increased 66% MoM, reaching 11.9K.
- Jul 12, 2026
Added GlaxoSmithKline, a pharmaceutical company, as a customer.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- partners_withSep 2, 2026
nference, Inc. and Rush University Medical Center launch a long-term partnership in Illinois on Sep 2nd '26 to create a secure, Rush University Medical Center-hosted platform for analyzing de-identified, longitudinal and multimodal clinical data.
For institutional investors. Book with your work email.
nference Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about nference's valuation, stock price, and market status.
Is nference a public or private company?
nference is a private company.
What is the current stock price of nference?
nference is a private company, so its shares have no public market price. Caplight tracks nference's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is nference worth (valuation)?
Valuation information for nference is not publicly available.
Can I buy nference stock?
nference shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was nference's last funding round?
nference's most recent funding round was Accelerator on December 1, 2022.
Who are the main investors in nference?
Key investors in nference include Matrix, Matrix Capital Management.
Will nference IPO soon?
No public IPO plans have been announced for nference.
How can I track nference secondary market activity?
Caplight tracks bids, offers, and trades in nference's shares on secondary markets.